Bullish
Eli Lilly invests $4.5 billion in Indiana manufacturing to boost genetic medicine production.
Eli Lilly has committed an additional $4.5 billion across two of its Indiana manufacturing sites, bringing the total capital expansion in the state since 2020 to over $21 billion. This investment aims to support the production of Foundayo™ (orforglipron), Lilly's first FDA-approved oral weight-loss pill, and retatrutide, an investigational triple hormone receptor agonist for obesity and cardiometabolic diseases. The expansion includes the opening of Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility.
Key points
- Eli Lilly's $4.5 billion investment in Indiana manufacturing sites to enhance genetic medicine production.
- Opening of Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility.
- Production of Foundayo™ (orforglipron), Lilly's first FDA-approved oral weight-loss pill.
- Development of retatrutide, an investigational triple hormone receptor agonist for obesity and cardiometabolic diseases.
Sources
AI-generated from public news sources. Not financial advice.
